Johnson Financial Group Inc (Wisconsin)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7	Closed	-$2.32K	–	821
2026 Q1	$2.32K	Hold	7	–	–	﹤0.01%	771
2025 Q4	$2.78K	Sell	7 -5	-42%	-$2.21K	﹤0.01%	771
2025 Q3	$5.47K	Buy	+12	New	+$4.89K	﹤0.01%	839
2024 Q3	–	Sell	-1	Closed	-$243	–	916
2024 Q2	$243	Buy	+1	New	+$158	﹤0.01%	815
2024 Q1	–	Sell	-1	Closed	-$192	–	782
2023 Q4	$192	Buy	+1	New	+$170	﹤0.01%	878

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s ALNY Position: Q2 2026 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 7 shares — an estimated $2.32K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in ALNY in Q4 2023 and held it in 5 quarters. The position peaked at $5.47K in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Johnson Financial Group Inc (Wisconsin) reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Johnson Financial Group Inc (Wisconsin) sold 7 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.32K.
Johnson Financial Group Inc (Wisconsin) first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 5 quarters.
Johnson Financial Group Inc (Wisconsin)'s Alnylam Pharmaceuticals position peaked at $5.47K in Q3 2025.
784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q2 2026, filed 10 Aug 2026.